Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

Hoag Cancer Center, Newport Beach, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Newport Beach, CA
Treatments:ImmunotherapyHospital:Hoag Cancer Center
Drugs:Journal:Link
Date:Apr 2006

Description:

Patients: This phase II trial involved 36 patients (25 men, 11 women) with metastatic kidney cancer. The median age was 57 years. Metastatic sites were lung, lymph nodes, bone, liver, adrenal gland, and kidney bed. Thirty-one had had a nephrectomy, 29 had no prior chemotherapy or biotherapy, 8 had prior radiation therapy, 7 had prior biotherapy, and 4 had prior chemotherapy.

Treatment: All 36 patients were treated with the immune therapy interleukin-alpha-2b.

Toxicity: 24 grade 4 toxicities were reported: creatinemia, hepatic, cardiovascular, neurological, rash, pruritis, fever, infection, fatigue, chills, myalgia. The most common grade 3 or 4 toxicities were fatigue, renal insufficiency, and hypotension. One patient died within 2 months of starting therapy, who had rapidly progressing disease, and developed renal insufficiency.

Results: The median overall survival was 15 months. The median progression free survival was 2.5 months. 35 patients were evaluated for their responses, no information was available on one patient except that he survived 2.5 years after starting treatment.

Correspondence: Dr. Robert O. Dillman




Back